Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant ipilimumab versus high-dose interferon alfa-2b for resected high-risk melanoma
2011-004257-29Phase 3Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ipilimumab and interferon alfa-2b in melanoma (3 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Recurrence-free survival. Started Nov 2012; status: completed.
02
Drugs
ipilimumabinterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-004257-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004257-29.